TABLE 1.
Basic characteristics of the included trials.
| Study | Sample size | Male/female | Age/(year) | Course of disease/(day or hour) | Intervention group | Control group | Duration/(day) | Outcomes | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | XNJ | Combined with treatment | Efficacy | Safety | |||
| He, (2021) | 47 | 47 | 24/23 | 25/22 | 58.24 ± 8.34 | 58.46 ± 6.79 | (4–24) h | (4–25) h | Xingnaojing injection 10 ml/d | CTs | CTs | 30 | 2) 8) | - |
| Dong et al. (2021) | 62 | 62 | 32/30 | 33/29 | 58.59 ± 2.27 | 58.61 ± 2.31 | (0–4.5) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 10) 11) | |
| Chen, (2021) | 45 | 45 | 20/25 | 22/23 | 60.4 ± 6.8 | 59.6 ± 6.5 | (2.4 ± 0.9) h | (2.2 ± 0.8) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | - |
| Wu and Xu, (2020) | 50 | 50 | 28/22 | 30/20 | 61.33 ± 9.81 | 60.86 ± 10.63 | (1.36 ± 0.61) d | (1.45 ± 0.67) d | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) 6) 7) 8) | - |
| Zhao, (2020) | 47 | 46 | 23/24 | 23/23 | 62.79 ± 9.34 | 62.39 ± 10.43 | (0–14) d | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 6) 8) | 10) 11) | |
| Zhang, (2020) | 30 | 30 | 18/12 | 17/13 | 64.81 ± 6.94 | 64.89 ± 6.97 | (3.45 ± 0.86) h | (3.48 ± 0.85) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 10) 11) |
| Liu, (2020) | 45 | 45 | 31/14 | 27/18 | 66.69 ± 6.98 | 67.42 ± 8.02 | (0–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 30 | 2) 4) 5) | 10) 11) | |
| Liang et al. (2020) | 43 | 43 | 29/14 | 27/16 | 59.49 ± 4.92 | 59.37 ± 5.28 | (13.92 ± 2.65) h | (13.85 ± 2.17) h | Xingnaojing injection 10–20 ml/d | CTs | CTs | 14 | 2) 5) 6) 7) 8) | 10) 11) |
| Liu H et al. (2019) | 42 | 42 | 26/16 | 24/18 | 51.28 ± 6.14 | 51.69 ± 6.20 | (0–72) | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) | - | |
| Zheng et al. (2019) | 43 | 43 | 26/17 | 27/16 | 59.74 ± 7.97 | 60.12 ± 8.23 | (3–4) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 4) 5) | 11) | |
| Yin and Liu, (2018) | 45 | 45 | 24/21 | 25/20 | 61.3 ± 12.70 | 60.8 ± 13.20 | (23 ± 2.7) h | (24 ± 2.2) h | Xingnaojing injection 40 ml/d | CTs | CTs | 14 | 2) | - |
| Ma, (2018) | 43 | 43 | 19/24 | 21/22 | 57.76 ± 3.32 | 61.19 ± 3.71 | (18.76 ± 3.32) h | (19.46 ± 4.79) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 10) 11) |
| Xiao et al. (2018) | 70 | 70 | 48/22 | 47/23 | - | - | (4.65 ± 0.19) h | (4.49 ± 0.31) h | Xingnaojing injection 10–20 ml/d | CTs | CTs | 14 | 2) 6) 7) 8) | 11) |
| Guo, (2018) | 60 | 60 | 36/24 | 35/25 | 64.2 ± 12.63 | 63.3 ± 12.24 | (4.4 ± 0.49) h | (4.3 ± 0.58) h | Xingnaojing injection 20 ml/d | CTs | CTs | 10 | 2) 8) 9) | - |
| Fu, (2018) | 37 | 37 | 25/12 | 23/14 | 65.36 ± 6.21 | 65.41 ± 6.17 | - | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) | 10) 11) | |
| Lin et al. (2018) | 104 | 104 | 52/52 | 53/51 | 62.1 ± 5.3 | 61.3 ± 5.6 | (0–72) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 10) 11) | |
| Ji et al. (2017) | 63 | 63 | 30/33 | 35/28 | 62.4 ± 4.9 | 61.6 ± 4.5 | (24–120) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 1) 2) 5) | - | |
| Wang and Lu, (2017) | 49 | 49 | 27/22 | 26/23 | 67.41 ± 6.25 | 67.93 ± 6.14 | - | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) 6) 7) 8) 9) | - | |
| Wu et al. (2017) | 50 | 50 | 26/24 | 25/25 | 63.1 ± 3.4 | 64.2 ± 3.6 | (0–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 30 | 2) 5) | 11) | |
| Feng et al. (2017) | 45 | 45 | 23/22 | 24/21 | 64.14 ± 7.24 | 64.72 ± 9.21 | (0–72) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) 6) 7) | 10) 11) | |
| Wang et al. (2017) | 35 | 35 | 18/17 | 19/16 | 60.2 ± 6.2 | 61.7 ± 5.3 | (18.1 ± 6.2) h | (16.5 ± 5.9) h | Xingnaojing injection 30 ml/d | CTs | CTs | 14 | 2) 5) | 11) |
| Zhao, (2017) | 31 | 29 | 21/10 | 19/10 | 71.02 ± 7.31 | 70.52 ± 7.41 | (4.4 ± 0.49) h | (4.3 ± 0.58) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) | 11) |
| Shen et al. (2017) | 43 | 43 | 27/16 | 26/17 | 63.28 ± 6.48 | 62.54 ± 6.19 | (1–3) d | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 5) | 10) 11) | |
| Lu et al. (2016) | 35 | 35 | 18/17 | 19/16 | 60.1 ± 8.5 | 59.9 ± 8.7 | (0–1) d | Xingnaojing injection 30 ml/d | CTs | CTs | 14 | 2) | - | |
| Zhang and Ai, (2016) | 56 | 56 | 79/33 | 59 ± 9 | (23 ± 3) h | Xingnaojing injection 30 ml/d | CTs | CTs | 14 | 2) | - | |||
| Wei et al. (2016) | 90 | 90 | 59/31 | 56/34 | 65 ± 5 | 64 ± 5 | (2.2 ± 0.8) h | (2.4 ± 0.7) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) 4) | - |
| Chen and Wu, (2015) | 56 | 56 | 29/27 | 30/26 | 68.8 ± 7.3 | 68.3 ± 7.1 | - | Xingnaojing injection 20 ml/d | CTs | CTs | 21 | 2) 9) | - | |
| Yang and Li, (2015) | 58 | 58 | 33/25 | 37/21 | 63.7 ± 6.5 | 62.0 ± 6.1 | (0–48) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 11) | |
| Luo, (2014) | 60 | 60 | 35/25 | 38/22 | 60.2 ± 10.2 | 61.7 ± 11.2 | (38.12 ± 4.54) h | (41.58 ± 6.23) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) 5) | 11) |
| Wei and Cheng, (2014) | 30 | 30 | - | - | - | - | (6–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 11) | |
| Qian and Jia, (2013) | 40 | 40 | 19/21 | 16/24 | 61.2 ± 5.9 | 61.6 ± 6.3 | (0–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) 6) | - | |
| Dong and Fu, (2013) | 35 | 33 | 21/14 | 19/14 | 58.74 ± 7.63 | 59.2L ± 7.95 | - | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) | - | |
| Li et al. (2012) | 30 | 31 | 15/15 | 13/18 | 62 | 63 | (0–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) | 11) | |
| Zhang et al. (2012) | 33 | 32 | 20/13 | 18/14 | 68.7 ± 10.5 | 69.2 ± 10.8 | (0–24) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | - | |
| Tong and Zhu, (2012) | 64 | 66 | 38/26 | 40/26 | 61–85 | 62–84 | (0–72) h | Xingnaojing injection 30 ml/d | CTs | CTs | 14 | 3) | 11) | |
| Chen et al. (2012) | 41 | 41 | 26/15 | 20/21 | 65.2 ± 12.6 | 63.5 ± 13.8 | - | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 2) | 11) | |
| Guan, (2011) | 30 | 30 | 16/14 | 17/13 | 63.4 ± 10.7 | 61.4 ± 9.7 | - | Xingnaojing injection 30 ml/d | CTs | CTs | 14 | 4) | - | |
| Wu, (2009) | 54 | 52 | 30/24 | 30/22 | 63.45 ± 7.5 | 64.35 ± 7.36 | (0–72) h | Xingnaojing injection 20 ml/d | CTs | CTs | 14 | 3) 5) 6) 7) | - | |
XNJ, Xingnaojing injection; CTs, conventional treatments; C, control group; T, intervention group; 1), Functional independence rate; 2), NIHSS; 3), CSS; 4), ESS; 5), ADL; 6), IL-6; 7), TNF-α; 8), Hs-CRP; 9), MMP-9; 10), Incidence of adverse reactions; 11), Adverse events.